Clinical trial
Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for…
NCT00432172 · Spanish Breast Cancer Research Group, Other · Completed
Key facts
| NCT number | NCT00432172 |
|---|---|
| Title | Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients |
| Official title | "A Randomized Multicenter Phase II Trial to Evaluate the Effectiveness of Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients" |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Epirubicin, Cyclophosphamide, Docetaxel, Exemestane, Goserelin, Carboplatin |
| Enrollment | 189 |
| Start date | Apr 24, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Feb 7, 2007 |
| Last update posted | Apr 3, 2023 |
| Countries | Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: